BridgeBio's Share Price Surges on $1B Raise and Strong Infigratinib Momentum

BBIO shares jumped roughly 16% after BridgeBio Pharma announced a $1 billion preferred equity financing alongside a wave of positive clinical updates across its two lead franchises, acoramidis (marketed as Attruby) for ATTR-CM and infigratinib for achondroplasia.

The financing, led by Sixth Street with participation from HealthCare Royalty (a business of KKR), took the form of convertible preferred stock carrying a 7.00% dividend and an initial conversion price of roughly $137.79 per share, more than double the stock's 30-day volume-weighted average price ahead of the deal. BridgeBio said the capital will help fund up to three additional U.S. launches over the next 12 months, BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigratinib for achondroplasia, on top of Attruby's continued commercial ramp. On the clinical side, infigratinib's Phase 3 PROPEL 3 trial, recently published in the New England Journal of Medicine, showed a statistically significant gain in annualized height velocity versus placebo along with the first significant improvements in body proportionality and arm span reported in a placebo-controlled achondroplasia study, supporting a planned FDA submission in the third quarter of 2026. Separately, new Attruby analyses published in Circulation: Heart Failure pointed to early and sustained kidney-protective effects through Month 30, a potential differentiator among ATTR-CM therapies. Adding to the momentum, rival AstraZeneca and Ionis disclosed that their eplontersen drug (Wainua) missed the primary endpoint in the CARDIO-TTRansform trial for ATTR-CM, a result BofA analysts called "a big surprise" and a setback that reduces near-term competitive pressure on Attruby.

Taken together, the developments strengthen BridgeBio's near-term financial position while easing one of the more prominent competitive threats to the Attruby franchise. The premium pricing on the preferred raise and the involvement of established credit investors suggest the market is reading the deal as opportunistic capital for a multi-launch runway rather than a sign of cash-runway stress. Whether the momentum holds will likely depend on execution through infigratinib's regulatory review and Attruby's ability to extend its lead now that a key rival program has stumbled.

Related Stocks

• BBIO
• AZN